Six under-the-radar U.S.-focused cannabis picks Shirley Won Published May 19, 2021
unknown/iStockPhoto / Getty Images
U.S. cannabis stocks have taken a beating, providing a buying opportunity for investors looking to bet on a pot boom south of the border.
Optimism for marijuana legalization pushed by top Senate Democrats helped fuel a rally until February, but the sector sold off amid market concerns about rising interest rates and owning riskier securities as well as tightened financing by some brokerages to hedge funds.
Although federal reforms may be slower in coming, the U.S. industry is growing with more states legalizing medical and adult-use cannabis and some companies on the road to profitability.
A Cannabis Consolidation Binge Is Creating Top Tier Companies Two more major deals were announced on Tuesday.
As the year comes to a close, the cannabis industry is on a consolidation binge. Two big deals were announced today piling on after last week s big move by Aphria (APHA) and Tilray (TLRY) . Ayr Strategies (AYRWF) is buying Liberty Health Science (LHSIF) in a deal valued at $290 million, and Columbia Care (CCHWF) is buying privately-held Green Leaf Medical in a deal valued at $240 million.
Ayr Strategies
Florida
Ayr Strategies has grown quickly through acquisition and this latest purchase gets the company exposure in two of the three best medical markets in the country. The all-stock deal for Liberty is valued at $290 million. In this transaction, Ayr will be getting Liberty s 387-acre cultivation campus in Gainesville, FL with over 300,000 sq. ft. of current production facilities in operation, 28 open retail dispensaries, seven completed and ready-to-open dispens